Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders
© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd..
BACKGROUND: Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID-19 vaccine effectiveness (VE). This study evaluated risk of COVID-19 hospitalization and estimated mRNA VE stratified by psychiatric disorder status.
METHODS: In a retrospective cohort analysis of the VISION Network in four US states, the rate of laboratory-confirmed COVID-19-associated hospitalization between December 2021 and August 2022 was compared across psychiatric diagnoses and by monovalent mRNA COVID-19 vaccination status using Cox proportional hazards regression.
RESULTS: Among 2,436,999 adults, 22.1% had ≥1 psychiatric disorder. The incidence of COVID-19-associated hospitalization was higher among patients with any versus no psychiatric disorder (394 vs. 156 per 100,000 person-years, p < 0.001). Any psychiatric disorder (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.18-1.37) and mood (aHR, 1.25; 95% CI, 1.15-1.36), anxiety (aHR, 1.33, 95% CI, 1.22-1.45), and psychotic (aHR, 1.41; 95% CI, 1.14-1.74) disorders were each significant independent predictors of hospitalization. Among patients with any psychiatric disorder, aHRs for the association between vaccination and hospitalization were 0.35 (95% CI, 0.25-0.49) after a recent second dose, 0.08 (95% CI, 0.06-0.11) after a recent third dose, and 0.33 (95% CI, 0.17-0.66) after a recent fourth dose, compared to unvaccinated patients. Corresponding VE estimates were 65%, 92%, and 67%, respectively, and were similar among patients with no psychiatric disorder (68%, 92%, and 79%).
CONCLUSION: Psychiatric disorders were associated with increased risk of COVID-19-associated hospitalization. However, mRNA vaccination provided similar protection regardless of psychiatric disorder status, highlighting its benefit for individuals with psychiatric disorders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Influenza and other respiratory viruses - 18(2024), 3 vom: 16. März, Seite e13269 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Levy, Matthew E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anxiety disorders |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 20.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/irv.13269 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369838750 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369838750 | ||
| 003 | DE-627 | ||
| 005 | 20240320234750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/irv.13269 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM369838750 | ||
| 035 | |a (NLM)38494192 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Levy, Matthew E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID-19 vaccine effectiveness (VE). This study evaluated risk of COVID-19 hospitalization and estimated mRNA VE stratified by psychiatric disorder status | ||
| 520 | |a METHODS: In a retrospective cohort analysis of the VISION Network in four US states, the rate of laboratory-confirmed COVID-19-associated hospitalization between December 2021 and August 2022 was compared across psychiatric diagnoses and by monovalent mRNA COVID-19 vaccination status using Cox proportional hazards regression | ||
| 520 | |a RESULTS: Among 2,436,999 adults, 22.1% had ≥1 psychiatric disorder. The incidence of COVID-19-associated hospitalization was higher among patients with any versus no psychiatric disorder (394 vs. 156 per 100,000 person-years, p < 0.001). Any psychiatric disorder (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.18-1.37) and mood (aHR, 1.25; 95% CI, 1.15-1.36), anxiety (aHR, 1.33, 95% CI, 1.22-1.45), and psychotic (aHR, 1.41; 95% CI, 1.14-1.74) disorders were each significant independent predictors of hospitalization. Among patients with any psychiatric disorder, aHRs for the association between vaccination and hospitalization were 0.35 (95% CI, 0.25-0.49) after a recent second dose, 0.08 (95% CI, 0.06-0.11) after a recent third dose, and 0.33 (95% CI, 0.17-0.66) after a recent fourth dose, compared to unvaccinated patients. Corresponding VE estimates were 65%, 92%, and 67%, respectively, and were similar among patients with no psychiatric disorder (68%, 92%, and 79%) | ||
| 520 | |a CONCLUSION: Psychiatric disorders were associated with increased risk of COVID-19-associated hospitalization. However, mRNA vaccination provided similar protection regardless of psychiatric disorder status, highlighting its benefit for individuals with psychiatric disorders | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a anxiety disorders | |
| 650 | 4 | |a electronic health records | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a mental disorders | |
| 650 | 4 | |a mood disorders | |
| 650 | 4 | |a psychotic disorders | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Yang, Duck-Hye |e verfasserin |4 aut | |
| 700 | 1 | |a Dunne, Margaret M |e verfasserin |4 aut | |
| 700 | 1 | |a Miley, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Irving, Stephanie A |e verfasserin |4 aut | |
| 700 | 1 | |a Grannis, Shaun J |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Zachary A |e verfasserin |4 aut | |
| 700 | 1 | |a Griggs, Eric P |e verfasserin |4 aut | |
| 700 | 1 | |a Spark, Talia L |e verfasserin |4 aut | |
| 700 | 1 | |a Bassett, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Embi, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Gaglani, Manjusha |e verfasserin |4 aut | |
| 700 | 1 | |a Natarajan, Karthik |e verfasserin |4 aut | |
| 700 | 1 | |a Valvi, Nimish R |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, Toan C |e verfasserin |4 aut | |
| 700 | 1 | |a Naleway, Allison L |e verfasserin |4 aut | |
| 700 | 1 | |a Stenehjem, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Nicola P |e verfasserin |4 aut | |
| 700 | 1 | |a Link-Gelles, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a DeSilva, Malini B |e verfasserin |4 aut | |
| 700 | 1 | |a Kharbanda, Anupam B |e verfasserin |4 aut | |
| 700 | 1 | |a Raiyani, Chandni |e verfasserin |4 aut | |
| 700 | 1 | |a Beaton, Maura A |e verfasserin |4 aut | |
| 700 | 1 | |a Dixon, Brian E |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Suchitra |e verfasserin |4 aut | |
| 700 | 1 | |a Dascomb, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Palak |e verfasserin |4 aut | |
| 700 | 1 | |a Mamawala, Mufaddal |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Jungmi |e verfasserin |4 aut | |
| 700 | 1 | |a Fadel, William F |e verfasserin |4 aut | |
| 700 | 1 | |a Barron, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Grisel, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Dickerson, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, I-Chia |e verfasserin |4 aut | |
| 700 | 1 | |a Arndorfer, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Najdowski, Morgan |e verfasserin |4 aut | |
| 700 | 1 | |a Murthy, Kempapura |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Caitlin |e verfasserin |4 aut | |
| 700 | 1 | |a Tenforde, Mark W |e verfasserin |4 aut | |
| 700 | 1 | |a Ball, Sarah W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Influenza and other respiratory viruses |d 2007 |g 18(2024), 3 vom: 16. März, Seite e13269 |w (DE-627)NLM176605215 |x 1750-2659 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2024 |g number:3 |g day:16 |g month:03 |g pages:e13269 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/irv.13269 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2024 |e 3 |b 16 |c 03 |h e13269 | ||